Stock RGRX REGENERX BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages RegeneRx Biopharmaceuticals, Inc.

Equities

RGRX

US75886X3061

Delayed OTC Markets
Other stock markets
 13:09:18 2024-06-21 EDT 		5-day change 1st Jan Change
0.0014 USD -.--% Intraday chart for RegeneRx Biopharmaceuticals, Inc. -.--% +16.67%
2023 RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A. CI
2023 RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Regenerx Licensee Submits Special Protocol Assessment to Fda for 4Th Phase 3 Clinical Trial for Dry Eye Disease
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
RegeneRx Biopharmaceuticals, Inc. Reports that Researchers Demonstrate the Therapeutic Efficacy of Thymosin Beta 4
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGRX Stock
  4. News RegeneRx Biopharmaceuticals, Inc.
  5. Other languages